Ebola vaccine technology could speed up development of other vaccines

In addition to an Ebola vaccine, the Coalition for Epidemic Preparedness Innovations is currently funding the development of vaccines for Lassa fever, Middle East respiratory syndrome, Nipah virus, and coronavirus at the Jenner Institute; and by using the same technology as the Ebola vaccine — called viral vectors — researchers can significantly reduce the time it takes to develop vaccines.

CEPI Awards Contract Worth Up To $19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced a collaboration to advance the development and manufacture of a vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) along with preclinical development of novel vaccines against Lassa and Nipah viruses.

CEPI announces new collaboration and funding for Lassa vaccine

According to terms of the agreement, Profectus will receive $4.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the first phase of its Lassa vaccine project, with an option to invest up to a total of $36 million over five years, which could cover procuring vaccine for stockpiling.

IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development

The International AIDS Vaccine Initiative (IAVI) has entered into a license agreement with the Public Health Agency of Canada (PHAC) toward advancing development, regulatory approval, and supply of a new vaccine candidate against Lassa fever virus